Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.
In patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis, use of an interleukin (IL)17-inhibitor does not contribute to an increase in the risk of inflammatory bowel disease (IBD) when compared with etanercept, according to a study.
Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
Faecal microbiota transplantation (FMT) does not appear to be beneficial in the treatment of active peripheral psoriatic arthritis, with a recent study showing that although FMT does not increase the incidence of serious adverse events, it is inferior to sham.
In a tightly monitored treatment setting, female patients with psoriatic arthritis (PsA) have greater disease severity than their male peers, as shown in a study. Being overweight is a notable risk factor for higher disease activity in women, but not in men.
Treatment with the selective interleukin-23 inhibitor guselkumab results in the clearance of enthesitis for many psoriatic arthritis (PsA) patients, with the resolution maintained through month 12, as shown by pooled data from two phase III trials.
Secukinumab, at both 300 and 150 mg, scores high in the management of psoriatic arthritis (PsA) patients with axial manifestations and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs), as shown in the results of the phase III MAXIMISE trial.
Among biologic‐naïve patients with psoriatic arthritis (PsA), continued ixekizumab therapy is more effective than discontinuation at sustaining low disease activity, according to data from a randomized, double‐blind withdrawal study.
Some psoriatic arthritis (PsA) patients still experience substantial pain and fatigue despite treatment, a study has shown. These persisting conditions negatively affect health-related quality of life (HRQoL), physical function, and work productivity.